Skip to content

NEUP

Neuphoria Therapeutics Inc.

NASDAQ · Healthcare · Medical - Pharmaceuticals · US

$3.70
−0.40%
Ask drillr
0
Insider buys (3m)
0
Insider sells (3m)
$0.00
Net value (3m)
-15.2%
Price return (3m)
Form 4 filings
DateInsiderActivitySharesPrice
Jan 21, 2026Wilson David Ian · directorA-Award8,537$0.00
Jan 21, 2026Davies Peter Miles Winston · directorA-Award8,537$0.00
Jan 21, 2026Fisher Alan · directorA-Award17,073$0.00
Jan 21, 2026Ryan Jane · directorA-Award8,537$0.00
Oct 23, 2025Lynx1 Capital Management LP · 10 percent ownerPurchase639,110$5.14
Sep 2, 2025Papapetropoulos Spyros · director, officer: President and CEOA-Award34,559$8.27
May 19, 2025Papapetropoulos Spyros · director, officer: President and CEOA-Award27,000$5.16
Apr 18, 2025Papapetropoulos Spyros · director, officer: President and CEOA-Award270,000$5.16
Apr 18, 2025Davies Peter Miles Winston · directorA-Award6,783$0.00
Apr 18, 2025Ryan Jane · directorA-Award6,783$0.00
Apr 18, 2025Wilson David Ian · directorA-Award6,783$0.00
Apr 18, 2025Fisher Alan · directorA-Award13,566$0.00
Institutional positioning

13F filings over the trailing two quarters

New 12Increased 11Reduced 5Sold out 3
FilerActionSharesFiled
Lynx1 Capital Management LPUnchanged875,328Aug 13, 2026
LYNX1 CAPITAL MANAGEMENT LPIncreased875,328May 4, 2026
AdvisorShares Investments LLCIncreased252,909Aug 11, 2026
VANGUARD CAPITAL MANAGEMENT LLCIncreased173,488Aug 13, 2026
Shay Capital LLCIncreased155,822Aug 14, 2026
ADVISORSHARES INVESTMENTS LLCIncreased155,367Apr 28, 2026
SHAY CAPITAL LLCReduced151,010May 15, 2026
BALYASNY ASSET MANAGEMENT L.P.Increased142,228Aug 14, 2026
BALYASNY ASSET MANAGEMENT L.P.New Position142,183May 15, 2026
VANGUARD CAPITAL MANAGEMENT LLCNew Position98,516May 15, 2026
Squadron Capital Management LLCNew Position76,728May 15, 2026
CITADEL ADVISORS LLCIncreased72,559Sep 2, 2026
GEODE CAPITAL MANAGEMENT, LLCIncreased52,007May 15, 2026
GEODE CAPITAL MANAGEMENT, LLCReduced49,516Aug 12, 2026
IKARIAN CAPITAL, LLCUnchanged47,443May 15, 2026

Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Jan 21, 2026